Small Molecules

09 Feb 2018 Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer's trials
08 Feb 2018 ZYTIGA® (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
08 Feb 2018 Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)
08 Feb 2018 Innovation Pharmaceuticals Concludes Successful Phase 2a Trial of Kevetrin for Ovarian Cancer; Intra-Tumor Modulation of p53 Observed
08 Feb 2018 Tyme Announces Interim Phase II Safety and Efficacy Data for SM-88 in Prostate Cancer at 2018 ASCO Genitourinary Cancers Symposium
08 Feb 2018 Sosei Provides an Update on Its Immuno-Oncology Clinical Program with AstraZeneca
08 Feb 2018 U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection
08 Feb 2018 Acesion Pharma Receives Approval for Phase I Study in Atrial Fibrillation
07 Feb 2018 Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder
07 Feb 2018 Exelixis Announces Updated Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Genitourinary (GU) Tumors
07 Feb 2018 Xcovery Announces Initiation of Phase 2 Clinical Trial for Ensartinib in Melanoma Patients with ALK Alternations
07 Feb 2018 SIGA Technologies Announces FDA Accepts NDA and Grants Priority Review for Oral TPOXX to Treat Smallpox
07 Feb 2018 Impel NeuroPharma Announces Positive Results of Phase 1 Clinical Trial of INP104 for Treatment of Acute Migraine Headache
07 Feb 2018 Verastem Submits New Drug Application to U.S. FDA for Duvelisib for the Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
07 Feb 2018 Brilinta significantly reduces CV events and coronary death beyond one year in heart attack survivors with multi-vessel disease
06 Feb 2018 Encorafenib and Binimetinib Combination Treatment Demonstrates 33.6 Month Median Overall Survival (OS) in Patients with BRAF-Mutant Melanoma in Phase 3 COLUMBUS Trial
06 Feb 2018 Celgene Corporation Announces Positive Results from the Pivotal Phase III ‘OPTIMISMM' Study of POMALYST/IMNOVID® for the Treatment of Relapsed or Refractory Multiple Myeloma
06 Feb 2018 Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine
06 Feb 2018 Palatin Technologies, Inc. Initiates Subject Dosing in First-in-Human Clinical Study of PL-8177, an Investigational Melanocortin Receptor 1 Agonist
06 Feb 2018 Trethera Corporation Announces FDA Clearance of Investigational New Drug Application for TRE-515
06 Feb 2018 FDA Clears Oricula Therapeutics Investigational New Drug Application for Clinical Trials
06 Feb 2018 Phase 3 PROSPER Trial Shows XTANDI® (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer
06 Feb 2018 Paratek Completes Submission of New Drug Applications to U.S. Food and Drug Administration for Oral and Intravenous Omadacycline for Pneumonia and Skin Infections
06 Feb 2018 AMAG Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application (sNDA) for Feraheme® (ferumoxytol injection)
06 Feb 2018 EyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract Surgery

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing